Agenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients
|
|
- Abraham Fletcher
- 5 years ago
- Views:
Transcription
1 The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Dr. Keiji Kijima, Secretary General, IPEC Japan April 26, 2012 Agenda JPE (Japanese ) JP (Japanese Pharmacopoeia) MF (Master File System) GAB (GMP Auditing Board) others are substances(s) other than drug substance(s) contained in preparations which are used to increase the utility of the preparation, to enable manufacturing of drug products easy, to keep product s integrity, to improve the appearance of a formulation and so forth. For these purposes, suitable excipients may be added in the drug manufacturing. The excipients used, however, must be non-toxic, harmless and pharmacologically inactive in the amount administered and must not interfere with the therapeutic efficacy or the quality test of the preparations. (JP16) 1
2 Notification JPE Public consultation Study Committee Proposal IPEC Japan (Council) Japanese Pharmaceutical Excipient (JPE) As preparation technologies are advanced and preparation designs are diversified, the role of pharmaceutical excipients is increasing in the characteristics such as dissolution, stability, solubility, etc. Japanese Pharmaceutical Excipient (JPE) Ministry of Health, Labor and Welfare (MHLW) announced the standards of the pharmaceutical excipients not included in Japanese Pharmacopoeia by the publication of Japanese. Total Monogrphs Japanese monographs Japanese Pharmaceutical Excipients/Supplement monographs supplied and 1 monograph deleted ---Total 297 monographs 2
3 Total Monogrphs Total Monogrphs JPE monographs supplied Total monographs 396 Japanese monographs supplied and 2 monographs deleted ---Total 436 monographs Japanese monographs added and 1 monographs deleted ---Total 479 For the Revised Japanese (JPE) 2012 For the Revised Japanese (JPE) 2012 MHLW started the committee for the revision of JPE in The committee has been held 9 times till Dec [Expected: Revised---approx. 40 monographs; New---approx. 12 monographs] The public comment will be collected in spring of A notification will be given by a chief of the bureau in charge in summer. 3
4 Situation of Japanese (JPE) Situation of Japanese Pharmaceutical Excipients (JPE) JPE consists of pharmaceutical excipients not included in Japanese Pharmacopoeia as well as those having precedent use and often used for the marketable pharmaceutical preparations. There are also pharmaceutical excipients specified in attachment in the application of approval of medicines Therefore, it is useful for pharmaceutical companies to apply for the approval of medicines. The pharmaceutical excipients, not applied to GMP, are applicable to SELF-IMPOSED STANDARDS FOR MANUFACTURING CONTROL OF PHARMACEUTICAL EXCIPIENTS (SELF- IMPOSED GMP). Judgment of advisability Judgment of advisability JPE is provided to determine the standards concerning General Notices, Preparations, Descriptions, Storages, etc. The pharmaceutical excipients are to be tested according to the provisions given in General Notice, General Tests and the pertinent monographs. The items of the Description in the monographs are given for the information, and should not be taken as indicating standards for conformity. 4
5 Situation of Japanese Pharmaceutical Excipients (JPE) Situation of Japanese Pharmaceutical Excipients (JPE) Unless otherwise specified in General Notices, General Tests and the pertinent monographs, the provisions given in General Notice, General Tests in JP 16 shall be applied. For pharmaceutical excipients specified in JPE Monographs which are manufactured as source materials derived from animals, the relevant animals must be healthy in principle, unless otherwise specified. Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No.145, 1960), the Japanese Pharmacopoeia (hereinafter referred to as new Pharmacopoeia ), which has been established as follows*, shall be applied on April 1, *The term as follows here indicates the contents of the Japanese Pharmacopoeia Sixteenth Edition from General Notices to Ultraviolet-visible Reference Spectra (pp ) The official name of this pharmacopoeia is 第十六改正日本薬局方, and may be abbreviated as 日局十六, 日局 16, JP XVI or JP 16. The English name of the pharmacopoeia is The Japanese Pharmacopoeia, Sixteenth Edition. 5
6 JP Edition Publication Outline Monographs JP 年 272 JP Supplement I partial revision Glycerin (DEG) 1567 partial revision Heparin Sodium (OSCS) 1567 partial revision Supplement II partial revision JP JP 16 th Edition carries 1764 articles, owing to the addition of 106 articles and the deletion of 15 articles. Ministerial Notification based on Pharmaceutical Affairs Law Final Draft JP Public consultation JP Committee PMDA (Expert Committee) The following items in General Tests, Processed and Apparatus were revised: 2.01 Liquid Chromatography 2.46 Residual Solvents Test 2.51 Conductivity Measurement 2.54 ph Determination 2.58 X-Ray Powder Diffraction Method 3.01 Determination of Bulk and Tapped Densities and so on. Total 15 items 6
7 Master File System for Drug Substances The harmonized General Tests and Monographs among the Japanese Pharmacopoeia, the European Pharmacopoeia and the United States Pharmacopeia are preceded by the statement as such. The parts of the test, being not harmonized, are surrounded by the symbols( ). Based on the Revised Pharmaceutical Affairs Law which was enforced on April 1, 2005, Master File Systems (MF) had been implemented ever since in Japan. Master File System for Drug Substances However, concerning existing pharmaceutical excipients, it is considered appropriate to refrain from submitting application of MF in Japan at present based on the PFSB/ELD Notification No issued by Ministry of Health, Labor and Welfare on February 10, Scope of MF Utilization Applications of MF registrations and changes to registered contents and notifications of minor changes to the registered contents shall be submitted to the Pharmaceuticals and Medical Devices Agency (hereinafter referred to as PMDA ), pursuant to the procedures and forms specified in the Enforcement Regulations of the Pharmaceutical Affairs Law (MHW Ministerial Ordinance No.1, 1961). 7
8 Items for registration The following raw materials to be used for the manufacture of pharmaceuticals and medical devices can be registered in MF. Items for registration 1. Drug substances, intermediates and pharmaceutical product materials (materials of pharmaceutical products with special dosage form, etc.) 2. New excipients and pre-mix excipients with a different composition ratio from existing ones 3. Materials for medical devices 4. Containers / packaging materials Items for registration Drug substances, intermediates and pharmaceutical product materials (materials of pharmaceutical products with special dosage form, etc.) used for OTC drugs (excluding OTC with new active ingredients or those with their active ingredients still in the reexamination period) are not appropriate for registration in MF, as it is considered that their quality and safety are already established even with existing specification and test methods. SELF-IMPOSED STANDARDS FOR MANUFACTURING CONTROL OF PHARMACEUTICAL EXCIPIENTS (SELF-IMPOSED GMP) As the pharmaceutical excipients in JP 16 are generally classified as Medicine, they should follow the GMP standard. Among them, 108 monographs receive the application of the GMP HARDWARE, but avoid the application of GMP SOFTWARE. IPEC Japan started the work to edit SELF- IMPOSED GMP since The process is as follows: 8
9 SELF-IMPOSED GMP GMP SOFTWARE SELF-IMPOSED GMP GMP HARDWARE Established April 1, 1996 Established April 1, 1998 The 1 st revised version October 1, 2006 The 1 st revised version October 1, 2006 The 2 nd revised version December 7, 2006 SELF-IMPOSED GMP VALIDATION STANDARDS SELF-IMPOSED GMP COLLECTION OF Q & A Change of management, Deviation of management and Addition of Q & A about the validation standards Established October 1, 2006 Established April 1,
10 SELF-IMPOSED GMP GUIDANCE BOOK FOR PLACTICE <Revision> Established December 1, 2010 In order not to interfere with enforcing the selfimposed GMP, explanatory information, matters to be checked or attended, and Q&A are supplemented to each articles. English Version English version of SELF-IMPOSED GMP AND ITS EXPLANATION was completed on December 1, 2011 to inform our GMP to foreign countries. In addition, the GMP Committee of IPEC Japan is making a comparison of SELF- IMPOSED GMP with ICH Q7 or IPEC Joint GMP to understand GMP at the level of the international standard. GMP Auditing Board for According to MHLW Ministerial Ordinance about GQP; The manufacturers of APIs shall ensure that the production duties at the factory concerned are conducted properly and efficiently with manufacturing control and quality control. GMP Auditing Board for However, As for pharmaceutical excipients, the production duties are not established as legal requirements. 10
11 GMP Auditing Board for Pharmaceutical excipients are often used in common at plural pharmaceutical companies. In that case, It is a good policy for the pharmaceutical companies to reduce an audit burden by using audit result of the 3 rd party. GMP Auditing Board for The manufactures of pharmaceutical excipients can reduce a burden to accept an audit from every company that is using the same product, too. GMP Auditing Board for GMP Auditing Board for GMP Auditing Board for Pharmaceutical Excipients is established in 2005 to secure the quality of pharmaceutical excipients of our country and to raise the reliability of the manufacturers of pharmaceutical excipients. The Board evaluates the GMP situation enforced by the manufactures based on SELF-IMPOSED GMP STANDARDS, edited by IPEC Japan, and then performs appropriate authorization. 11
12 Outline of GMP Auditing Board for Advantage of GMP Auditing Board for The board audits the pharmaceutical excipients company whether the company conducts production duties at the manufacturing site concerned properly and efficiently with manufacturing control and quality control. Therefore, the pharmaceutical company might secure the good quality and reliability of the pharmaceutical excipient product effectively if passed the audition. Japanese Directory by IPEC Japan The number of Pharmaceutical excipients, which have been used so far, is 1228 monographs according to Japanese Directory But among them, about 200 monographs are listed in JP 16. Japanese Directory by IPEC Japan Pharmaceutical excipients which are generally used in the process of dosage form formulation play an important role in securing the quality, efficacy and safety through maintaining the dosage form and stabilizing the drug. In association with higher levels of pharmaceutical technology and diversified dosage forms in recent years, the role of pharmaceutical excipients has been increasing. For the purpose of appropriate use of pharmaceutical excipients, the Japanese edition of Japanese Pharmaceutical Excipients Directory (JPED) was published on the basis of collective investigations of the available information on definitions, properties, specifications, uses, maximum dose and so forth related to approval drugs. 12
IPEC Japan Update. Keiji Kijima Ph.D. Feb. 6 th, 2015 Hotel Negresco Nice (France)
IPEC Japan Update Keiji Kijima Ph.D. Feb. 6 th, 2015 Hotel Negresco Nice (France) ::Contents:: 1. Self-Imposed Standards of Excipients GMP 2014 2. The Japanese Pharmaceutical Excipients Directory (JPED)
More information::Contents:: IPEC Japan Update. 1. Self-imposed Standards of Excipient GMP Self-imposed Standards of Excipient GMP 2014
::Contents:: IPEC Japan Update Keiji Kijima Ph.D. Feb. 6 th, 2015 Hotel Negresco Nice (France) 1. Self-Imposed Standards of Excipients GMP 2014 2. The Japanese Pharmaceutical Excipients Directory (JPED)
More informationKazuhiko Mori Ministry of Health, Labour and Welfare
Kazuhiko Mori Ministry of Health, Labour and Welfare 1 1. The Establishment of the Japanese Pharmacopoeia 2. Revisions of the Japanese Pharmacopoeia and Changes in Pharmaceutical Regulation 3. Current
More informationPoints to Consider CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan
2013 CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan The Master File System and Points to Consider Kentaro Hashimoto, Master File Management Group, Division of Pharmacopoeia and Standards
More informationGuidance on Drug Master File System in Japan
2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master
More informationEVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationCHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS
CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of
More information- Notification to specify uniform limit (Ministry of Health, Labour and Welfare Notification No. 497, 2005)
Syoku-An No.1129001 November 29, 2005 *1 Director Notice *2 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Establishment of Applicable Laws and Ordinances
More informationRecognized Pharmacopoeia in Registration system
Recognized Pharmacopoeia in Registration system Mrs. Prapassorn THANAPHOLLERT Acting Director, Bureau of Control Food and, THAILAND What is pharmacopoeia? Legal basis Outline Recognized Official Pharmacopoeia
More informationOn Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
Administrative Notice 1 July 9, 2010 To: Pharmaceutical Affairs Divisions, Prefectural Public Health Bureaus (Departments) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau,
More informationOverview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan
1 5 th Joint Conference of Taiwan and Japan on Medical Products Regulation Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan Mr. Yoshihiko Sano Deputy Director,
More informationin the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use
Frequently Asked Questions Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions The Q4B Expert Working Group developed a set of frequently asked questions to help users
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationResearch on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version
Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File Division of Pharmaceuticals Department of Drug Registration Hou Renping Translation version Main
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationDirector-General, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Notice No. 0315 Article 1 of the Department of Food Safety March 15, 2012 To: All the Prefectural Governors All the Mayors in Cities with Public Health Centers All the Mayors of Special Wards Director-General,
More informationReports of Adverse Drug Reactions, etc. of Pharmaceuticals
(Attachment) Reports of Adverse Drug Reactions, etc. of Pharmaceuticals 1 GLOSSARY (1) Drugs, quasi-drugs, and cosmetics -1- Related to Article 228-20, paragraph 1, item 1 of the Enforcement Ordinance
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationReview Report. (11) Olanzapine Fine Granules 1% "DSEP" (14) Olanzapine OD Tablets 10 mg "DSEP" (17) Olanzapine Tablets 10 mg "Nichi-Iko"
Review Report November 13, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical products submitted for marketing approval conducted
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationJapan's Regulation of Food Additives
Japan's Regulation of Food Additives July 4, 2016 Daisuke Takeuchi Standards and Evaluation Division Department of Environmental Health and Food Safety Pharmaceutical Safety and Environmental Health Bureau,
More informationUSP Perspective on Atypical Actives November 29, 2017
USP Perspective on Atypical Actives November 29, 2017 USP Excipients Stakeholder Forum USP Perspective on Atypical Actives Catherine Sheehan, M.S., M.S. Senior Director, Science Excipients Outline Role
More information(Tentative Translation)
(Tentative Translation) Public Notice of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare (MHLW) No. 2 of December 17, 2010 Table
More informationOrganic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017
Organic Impurities in Drug Substances and Drug Products Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017 Potential sources of drug impurities during development AAPS PharmSciTech,
More informationIntroduction on the Regulations on Imported Nutrition Supplements of the Republic of China
Introduction on the Regulations on Imported Nutrition Supplements of the Republic of China Preface With the aging of population in Taiwanese society, the people of Taiwan have become more health-conscious
More informationREGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.
REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.
More informationReview Article ISSN: Open Access. Regulatory Aspects of Pharmaceutical Excipients in India and their Qualification to Use in Pharmaceuticals
Review Article ISSN: 2581-4559 Open Access UPI JOURNAL OF BUSINESS MANAGEMENT AND COMPUTER APPLICATIONS Journal Home Page: https://uniquepubinternational.com/upi-journals/upi-journal-ofbusiness-management-and-computer-applications-upi-jbmca/
More informationJapan's Approval Process for Food Additives
Japan's Approval Process for Food Additives 1 Definition and Scope of Food Additives in Japan Additives" mean substances that are used by being added, mixed or infiltrated into food or by other methods
More informationThe Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods
The Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods The Ministry of Health, Labour and Welfare revised Food Sanitation Law in May 2003. Based on the revised
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationBasic guidelines for promotion of control measures for hepatitis
Basic guidelines for promotion of control measures for hepatitis May 16, 2011 Table of Contents Chapter 1 Basic approach for preventing hepatitis and promoting medical care of hepatitis - 2 - Chapter 2
More informationUpdate on JP-TW OTC drugs WG
Update on JP-TW OTC drugs WG Fumihito Takanashi Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labor and Welfare (MHLW) 7, December,
More informationDr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013
The 7 truths of impurities and their reference standards FDA's and other regulators' viewpoints and further stories (Part 1) Dr. Christian Zeine LGC Standards GmbH Webinar Series 2013 July 2013 Quick guide
More informationCOMMISSION DELEGATED REGULATION (EU).../... of XXX
EUROPEAN COMMISSION Brussels, XXX SANTE/10355/2015 (POOL/E4/2015/10355/10355-EN. doc) [...1(2015) XXX draft COMMISSION DELEGATED REGULATION (EU).../... of XXX supplementmg Regulation (EU) No 609/2013 of
More informationOverview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017
Overview of USP General Chapters and Prescription/Non-Prescription Stakeholder Forum October 19, 2017 Introduction Periodic review of existing general chapters Typically an approximately 5
More informationGeneral Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe
General Concepts in the European Pharmacopoeia Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe General notices Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All
More informationIndian Pharmacopoeia Commission
Indian Pharmacopoeia Commission JP 130 th Anniversary Symposium Tokyo, Japan 15 th Sept, 2016 Dr.G.N.Singh Secretary cum Scientific Director, Overview Indian Pharmaceutical Industry Pharmacopoeia and NFI
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationRegarding Establishment of a Uniform Limit in a Positive List System concerning Agricultural Chemicals Residues in Food etc.
Regarding Establishment of a Uniform Limit in a Positive List System concerning Agricultural Chemicals Residues in Food etc. (Final Draft) In introducing a positive list system concerning agricultural
More informationPublic Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:
Public Assessment Report Scientific discussion Pentasa Compact 4 g, prolonged-release granules (mesalazine) NL License RVG: 114015 Date: 30 March 2015 This module reflects the scientific discussion for
More informationAnnouncement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines Act (AMG)
Federal Gazette No 127 dated 24 August 2011, p. 2975-2977 Federal Ministry of Health Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, March 2018 SANTE-2017-11668 Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment
More informationRequirements to the Registration of Medicinal products in the Republic of Armenia
Requirements to the Registration of Medicinal products in the Republic of Armenia Yerevan 2010 Requirements to the Registration of Medicinal products in the Republic of Armenia Current requirements to
More informationJapanese regulations and JSQA update. Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016
Japanese regulations and JSQA update Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016 Contents Japanese regulatory updates of the GxP systems Recent activities
More informationUSP <232> and <233> Understanding Your Path to Compliance with the New Elemental Impurity Chapters. Steve Wall Agilent Technologies
USP and Understanding Your Path to Compliance with the New Elemental Impurity Chapters Steve Wall Agilent Technologies Outline, USP - USP Chapter - Chapter Limits -
More informationCOMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES
COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental
More informationGeneral Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.
General Chapter/Section: Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No. of Commenters: 18 Editorial changes suggested by commenters have been reviewed by
More informationProvisional Translation Original: Japanese
Provisional Translation Original: Japanese Regarding Establishment of the level to be determined by the Minister of Health, Labour and Welfare, at the Pharmaceutical Affairs and Food Sanitation Council
More informationGUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE
CAMEVET PROCEEDINGS II REVIEW DATE in BRAZIL: HOMEOPATHIC COMMISSION - SINDAN August 18, 2016 GUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE SÃO PAULO, BRAZIL August 2016 Page 2 of 9 GUIDE TO
More informationPublic manual: Application for permission of a product and correction of permitted items: for food for weight control person Service agency:
Public manual: Application for permission of a product and correction of permitted items: for food for weight control person Service agency: Food and Drug Administration, Ministry of Public Health. Criteria,
More informationCARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:
RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription
More informationHeng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare
Heng-Jung Lien Section Chief Division of Medicinal Products, Food and Drug Administration, Ministry of Health and Welfare, Taiwan, R.O.C. 衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and
More informationTo: Director-general, Department of Health, Prefectural Governments. Points to Consider for the Instructions for Package Inserts of Prescription Drugs
Translated by PhRMA Japan (Pharmaceutical Research and Manufacturers of America Japan) and EFPIA Japan (European Federation of Pharmaceutical Industries and Associations Japan) with consultation to MHLW
More information3.7 Bracketing. 3.8 Matrixing
chemical characteristics of the dosage form, e.g. magnesium stearate (dissolution), sodium benzoate, (microbiological preservative), etc. 3.6 Liquids Dosage forms intended for oral administration or cutaneous
More informationKampo Formulations for Prescription Information in Package Inserts of 148 Formulations - 1 Dec 2018
Kampo Formulations for Prescription 2018 - Information in Package Inserts of 148 Formulations - 1 Dec 2018 Usability Research Subcommittee Ethical Kampo Products Committee Japan Kampo Medicines Manufacturers
More informationDIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/85 DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products,
More informationGuideline on quality of herbal medicinal products 1 /traditional herbal medicinal products
31 March 2011 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Committee on Herbal Medicinal Products (HMPC) Guideline on quality of herbal
More informationWorking Document prepared by the Commission services - does not prejudice the Commission's final decision 3/2/2014 COMMISSION STAFF WORKING DOCUMENT
COMMISSION STAFF WORKING DOCUMENT on certain requirements for FSMPs [Supporting Document for the Expert Group meeting of 7 February 2014] Introduction Following the discussions in the Expert Group meeting
More informationAGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)
AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION (Moscow, 23 December 2014) Member States of the Eurasian Economic Union, hereinafter referred
More informationIPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope
IPEC Europe Observations and Recommendations on Guidelines On The Formalised Risk Assessment For Ascertaining The Appropriate Good Manufacturing Practice For Excipients Of Medicinal Products For Human
More informationDisclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations
49th Annual Meeting Non-Sterile Compounding/ Sunil Jambhekar, B. Pharm., M.S., Ph.D Professor, Pharmaceutical Sciences LECOM Bradenton, School of Pharmacy Bradenton, FL 34211 Disclosure I do not have a
More informationH 7816 S T A T E O F R H O D E I S L A N D
LC00 01 -- H 1 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES Introduced By: Representatives Serpa, Canario,
More informationThailand s experience in developing the Reclassification guideline
Ms.Charunee Krisanaphan Pharmacist, Senior Professional level Standards and Regulations Division, Bureau of Control Thai Food and October 22, 2014 Outlines Definition Existed guideline Process of developing
More informationMEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA
MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA Document No.: MCA/NSG/17/11/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017
More informationGuidance for Industry
Guidance for Industry Dosage Delivery Devices for OTC Liquid Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationEMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use 25 October 1999 EMEA/HMPWP/23/99 EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS UPDATED DRAFT POINTS
More informationRecord of the Consultation on Pharmacogenomics/Biomarkers
This English version of the record of the consultation has been published by PMDA. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. (Attachment
More informationProgram to Promote Use of Generic Drugs in Japan
Program to Promote Use of Generic Drugs in Japan March 22, 2012 CPhI Japan 2012 Tsuyoshi Matsuno Economic Affairs Division, Health Policy Bureau, Ministry of Health, Labour and Welfare * A Japanese translation
More informationGuideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1
5 April 2016 EMA/HMPC/71049/2007 Rev. 2 Committee on Herbal Medicinal Products (HMPC) Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal
More informationGuideline for the Rational Use of Controlled Drugs
Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import
More informationAnnex. (Draft for Comments)
Annex Announcement on the Matters related to filing and Joint Review & Approval of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials for Drug Products
More informationORDINANCE NO
ORDINANCE NO. 01-2017 AN ORDINANCE OF THE CITY COUNCIL OF THE CITY OF SEMINOLE, FLORIDA, REGARDING MEDICAL CANNABIS; IMPOSING A TEMPORARY MORATORIUM ON THE SALE OF MEDICAL CANNABIS AND ON THE ESTABLISHMENT
More informationReview Article PHARMACEUTICAL EXCIPIENTS: GLOBAL REGULATORY ISSUES
Review Article Indonesian J. Pharm. Vol. 24 No. 4 : 215 221 ISSN-p : 2338-9427 DOI: 10.14499/indonesianjpharm24iss4pp215 PHARMACEUTICAL EXCIPIENTS: GLOBAL REGULATORY ISSUES Dinesh Kumar, Harish Dureja*
More informationPharmakon drug Poiea to make Government of each country List of Pharmacopeias: British European Indian International United state.
Pharmacopoeia Derived from Greek word Pharmakon means drug and Poiea means to make. It is a legal and official book issued by recognized authorities usually appointed by Government of each country. It
More informationH e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction
INTRODUCTION To the Recommendation by the Board of the Eurasian Economic Commission Dated 20 No H e r b a l M e dicines' Q U A L I T Y M ANUAL I. Introduction 1. The Herbal Medicines Quality Manual (hereinafter
More informationG O L D E N S E A L R O O T P O W D E R
T H E A M E R I C A N H E R B A L P R O D U C T S A S S O C I A T I O N S GUIDANCE CA PROPOSITION 65: G O L D E N S E A L R O O T P O W D E R AUGUST 2016 This document is the property of the American Herbal
More informationPROVISIONAL TRANSLATION
- 3 - CROATIAN PARLIAMENT 1035 Pursuant to Article 88 of the Constitution of the Republic of Croatia, I hereby issue the DECISION PROMULGATING THE ACT ON AMENDMENTS TO THE MEDICINAL PRODUCTS ACT I hereby
More information(Legislative acts) REGULATIONS
31.12.2010 Official Journal of the European Union L 348/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards
More informationExcipient Risk Assessment
Excipient Risk Assessment Richard O Sullivan- GMP Inspector GMP Conference 7 February 2017 Dublin Content Background 1 Guidance 2 HPRA Expectations 3 07/02/2017 2 Excipient Risk Assessment-Why? 07/02/2017
More informationRisk Classification of Excipients. Presentation to Stakeholders Meeting Brussels 14 th May 2009 Frithjof Holtz
Risk Classification of Excipients Presentation to Stakeholders Meeting Brussels 14 th May 2009 Frithjof Holtz Risk Classification of Excipients 1. Why Classification? 2. How will Classification work? 3.
More informationThe International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
More informationHaving regard to the opinion of the European Parliament. Having regard to the opinion of the Economic and Social Committee ( 3 ),
No L 86/ 30 Official Journal of the European Communities 6. 4. 79 COUNCIL DIRECTIVE of 2 April 1979 on the marketing of compound feedingstuffs (79/373/ EEC) THE COUNCIL OF THE EUROPEAN COMMUNITIES, Having
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 16 March 2006 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS DISCUSSION IN THE SUBGROUP STABILITY April / May 2008 DISCUSSION
More informationReview Report. Inavir Dry Powder Inhaler 20 mg
Review Report June 27, 2016 Pharmaceuticals and Medical Devices Agency The following are the results of a review of the following pharmaceutical product submitted for marketing approval conducted by the
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, European Medicines Agency PHARM 689 PHARMACEUTICAL COMMITTEE 21 October 2015
More informationThis Administrative regulation will come into force on 1 st August 2013 and will remain so until further notice.
Administrative regulation 01.08.2013 Dnro 4000/03.01.01/2012 2/2013 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation APPLYING FOR AND MAINTAINING A MARKETING AUTHORI- SATION AND
More informationon the approximation of the laws of the Member States concerning food additives authorized for use in foodstuffs intended for human consumption
11. 2. 89 Official Journal of the European Communities No L 40/ 27 COUNCIL DIRECTIVE of 21 December 1988 on the approximation of the laws of the Member States concerning food additives authorized for use
More informationFOOD ACT No.26 OF 1980
FOOD ACT No.26 OF 1980 REGULATIONS made by the Minister of Health in consultation with the Food Advisory Committee under section 32 of the Food Act No. 26 of 1980. Colombo 15 th November, 2005 Nimal Siripala
More informationAct on Narcotic Drugs and Psychotropic Substances and Precursors thereof
Issuer: Riigikogu Type: act In force from: 13.05.2016 In force until: 22.11.2018 Translation published: 06.05.2016 Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Amended by the
More informationChapter 11 How to state your conditions clearly to the doctor
Chapter 11 How to state your conditions clearly to the doctor Chapter 11 How to state your conditions clearly to the doctor While seeing doctor, details of your statement should include the following:
More informationMEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA
MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA Document No.: MCA/HMPG/17/12/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017 Version
More informationThis Administrative regulation will come into force on 1 st January 2018 and will remain so until further notice. Administrative Regulation No 3/2015
Administrative regulation 15.12.2017 Dnro 007313/00.01.02/2017 02/2017 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation APPLYING FOR AND MAINTAINING A MARKETING AUTHORI- SATION
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationGMP GMP. What is it and why do we need it? Dennis Reiswig. The FDA. USP & NF History. Regulatory Definitions. (Good Manufacturing Practices)
2007 Intertanko GMP Presentation GMP What is it and why do we need it? Dennis Reiswig Sr. Quality Specialist The Dow Chemical Company Regulatory Definitions GMP CFR FDA (Good Manufacturing Practices) (Code
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationAlignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference
Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Donald Kautter US Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food
More information